The General Hospital Corporation Research Management Division, doing business as Massachusetts General Hospital (MGH), has been awarded a $725,628 Project Grant (R01DK140780) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a 5-year research project to optimize and evaluate the use of the FDA-approved Ilet Bionic Pancreas automated insulin delivery system for achieving pregnancy-specific glycemic targets in individuals with type 1 and type 2 diabetes. The research aims to make feasible modifications to the Ilet device and then conduct clinical trials to compare the optimized pregnancy-specific settings to standard care in 36 pregnant participants. This work has the potential to transform diabetes care in pregnancy and improve maternal and neonatal health outcomes for the approximately 40,000 pregnancies affected by diabetes annually in the United States.
Generated 2/25/25, 3:33 AM